Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

For patients with stage IA non-small cell lung cancer (NSCLC), lung resections, including lobectomy and segmentectomy, are ...

Obesity was associated with improved overall survival (OS) after curative resection in patients with non-small cell lung cancer (NSCLC), particularly those who did not have low sk ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

For early-stage NSCLC, lobar resection has been the gold standard since 1995 with publication of the LCSG trial. Given that ...

New research presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that anatomic lung resections, ...

This study suggests that immunotherapy may not be the optimal ... New, Rare Type of Small Cell Lung Cancer Identified Sep. 11, 2024 — A team of doctors and researchers have identified a new ...

Since the application of molecular biology in cancer biology, lung cancer research has classically focused on molecular drivers of disease. One such pathway, the hypoxic response pathway, is ...

Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including targeted therapy. Teamwork: A Multidisciplinary Approach to ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...